Navigation Links
World-first swine-flu vaccine trial reveals one dose provides 'strong immune response'
Date:9/3/2009

Results from the first swine-flu vaccine trials taking place in Leicester reveal a strong immune response after just one dose.

The pilot study, run by the University of Leicester and Leicester Hospitals, was trialled with 100 healthy volunteers, aged between 18 and 50.

Dr Iain Stephenson, who led the trial at the Leicester Royal Infirmary, said: "The clinical trial of Novartis MF59-adjuvanted cell-based A (H1N1) vaccine indicates that the "swine flu" vaccine elicits a strong immune response and is well-tolerated.

"Results showed that the serum antibody responses were highest among subjects who received two doses of vaccine, however a single vaccine dose also induced responses associated with protection against influenza.

"The findings showed that it is possible to induce protective antibody against A(H1N1) infection within two weeks of administration of a single low-dose adjuvanted vaccine."

Non-adjuvanted formulations were not evaluated in this part of the study and will be evaluated shortly

The trial evaluated the tolerability and immunogenicity of the vaccine, and tested different schedules of vaccination, in terms of time between vaccinations. The vaccine schedule was one or two doses of 7.5μg MF-59 adjuvanted surface-antigen A/California/2009 vaccine derived from cell-culture.

Dr. Stephenson, of the Department of Infection, Immunity and Inflammation at the University of Leicester is a clinical senior lecturer at the University, and a consultant in infectious diseases at the University Hospitals of Leicester NHS Trust. He said: "The aim of the trial was to find out how many doses and what type of vaccine is needed to give protection. These initial results should help to plan vaccination campaigns in the autumn, including doses and timings. We concluded that the MF59-adjuvanted A(H1N1) vaccine of low antigen content was well tolerated and generated antibody responses associated with protection against influenza, even after a single dose."

"The results suggest that one vaccine dose may be sufficient to protect against the A(H1N1) swine flu, rather than two. Larger trials are already underway around the world. Timings on when the vaccine will be available to governments will depend on the results of these clinical trials, and approvals by regulatory authorities''

The research found the vaccine is well tolerated with pain at the injection site the most frequent adverse event.

Additional pivotal trials with both cell culture and traditional egg based vaccines under way around the world that will include more than 6000 adults and children.

Previous research had indicated that two doses of the vaccine would be needed against swine flu. You can access earlier stories here:


'/>"/>

Contact: Ather Mirza
pressoffice@le.ac.uk
44-011-625-23335
University of Leicester
Source:Eurekalert

Related biology news :

1. Study of African traditional medicine will begin world-first clinical trial
2. World-first to predict premature births
3. A world-first in solar technology unveiled at Concordia University
4. Britains first swine-flu trials under way
5. Possible hepatitis C vaccine
6. Study by Pittsburgh researchers identifies possible vaccine target for chlamydia
7. New nanoparticle vaccine is more effective but less expensive
8. Flu vaccine in painless skin patches under development at Emory, Georgia Tech with NIH grants
9. Influenza vaccine causes weaker immune response for children of rural Gabon than in semi-urban areas
10. An Alzheimers vaccine?
11. Penn researchers find monkeys able to fend off AIDS-like symptoms with enhanced HIV vaccine
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/4/2017)...  For the thousands of attendees at this year,s International Consumer Electronics ... and biometric measurement devices and services, will be featuring its new line ... A&D Medical,s special CES Exhibit Suite , the new upper arm ... company,s WellnessConnected product platform.  ... ...
(Date:1/3/2017)... LAS VEGAS , Jan. 3, 2017 ... announced the introduction of Onitor Track, an innovative biometric ... and men, showcasing this month at the 2017 Consumer ... . In the U.S., the World ... affect more than two-thirds of adults who are overweight ...
(Date:12/22/2016)... YORK , December 22, 2016 ... provider of secure solutions for the e-Government, Public Safety, HealthCare, and ... subsidiary of SuperCom, has been selected to implement and deploy a ... in Northern California , further expanding its presence ... ...
Breaking Biology News(10 mins):
(Date:1/12/2017)... , Jan. 12, 2017   Protein ... and maker of Flublok Influenza Vaccine ®, ... vaccine candidate had good safety results and induced ... preclinical studies. The product is expected to advance ... months.  In addition, the Institute of Technology in ...
(Date:1/12/2017)... ... January 12, 2017 , ... ... has enhanced the platform to accommodate increasingly complex and sophisticated deployments, resulting ... and more. In addition to these improvements, the latest release brings enhanced ...
(Date:1/11/2017)... ... January 11, 2017 , ... As a graduate student, ... the pathogens that cause malaria and tuberculosis. Seeing firsthand the ravages those diseases ... Now, as an assistant professor of biology and biotechnology at Worcester Polytechnic Institute ...
(Date:1/11/2017)... , ... January 11, 2017 , ... ... year and costing healthcare systems more than $23.7 billion, healthcare systems are ... , Among the most common sepsis-causing pathogens are bacteria and the yeast ...
Breaking Biology Technology: